Yu Kuramochi

No ORCID on file · 3 papers in corpus · active 2022-2023

Study types

  • other 3

Condition tags

  • endometriosis 3
other 2023
Suppression of hypothalamic-pituitary-gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models
Clinical and experimental pharmacology & physiology ·doi:10.1111/1440-1681.13817

The hypothalamic-pituitary-gonadal (HPG) axis is an important regulatory mechanism involved primarily in the development and regulation of the reproductive systems. The suppression of the HPG axis by gonadotropin-releasing hormone (GnRH) an…

other 2023
Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats
Clinical and experimental pharmacology & physiology ·doi:10.1111/1440-1681.13778

Endometriosis is an oestrogen-dependent disease in which endometrial-like tissue grows outside the uterus in women of reproductive age. Accordingly, control of oestradiol (E2) levels is an effective treatment for endometriosis. Because gona…

other 2022
Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors
Clinical and experimental pharmacology & physiology ·doi:10.1111/1440-1681.13688

Control of gonadotropin-releasing hormone (GnRH) signalling is an effective strategy for the treatment of sex hormone-dependent diseases. GnRH analogues have been widely used for treating these diseases; however, initial stimulation or comp…